Toxic Air Seen Adding To China Lung Cancer Surge
This article was originally published in PharmAsia News
Already the leading type of malignancy for both men and women in China, lung cancer is likely to strike the country even harder over the next decade, due to the expected ill effects of exposure to persistent and worsening air pollution, an official at the National Health and Family Planning Commission has warned.
You may also be interested in...
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.